{
  "content": "ABSTRACTS\nPurpose\nAntiarrhythmic drug (AAD) therapies are foundational in the long-term management of atrial fibrillation (AF), yet there remains uncertainty in clinical and reimbursement decisions in China. This study aimed to estimate the cost-effectiveness of dronedarone compare to amiodarone and sotalol for the treatment of paroxysmal or persistent AF in China from the health system perspective.\nMethods",
  "source": "https://www.sciencedirect.com/science/article/abs/pii/S0149291825002176",
  "chunk_id": "7d4a5505-0d1d-43a6-a7f2-91249e48c439",
  "similarity_score": 0.2686779499053955,
  "query": "cost effectiveness economic analysis amiodarone beta-blockers atrial fibrillation healthcare costs hospitalization reduction",
  "rank": 24,
  "title": "Cost-Effectiveness of Antiarrhythmic Drugs for Treating Paroxysmal or Persistent Atrial Fibrillation in China: An Economic Evaluation",
  "authors": "Fuming Li, Dunming Xiao, Yu Xia, Junling Weng, Shimeng Liu, Yingyao Chen",
  "year": "2025",
  "journal": "Clinical Therapeutics",
  "reference": "Li, F., Xiao, D., Xia, Y., Weng, J., Liu, S., & Chen, Y. (2025). Cost-effectiveness of antiarrhythmic drugs for treating paroxysmal or persistent atrial fibrillation in China: An economic evaluation. Clinical Therapeutics. https://doi.org/Not available",
  "doi": "Not available",
  "chunk_index": 2,
  "total_chunks": 30,
  "retrieved_at": "2025-07-24T21:58:16.915818"
}